Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4174 | V-SARS Wiki | 1.00 |
| drug2993 | Placebo-LDE phase 2 Wiki | 1.00 |
| drug2361 | Methotrexate-LDE phase 2 Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007249 | Inflammation NIH | 0.17 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The investigators propose a prospective, randomized, double-blind, placebo-controlled study, conducted in two phases. The purpose of the study is to evaluate the safety and efficacy of methotrexate in a cholesterol-rich non-protein nanoparticle (MTX -LDE) in adults diagnosed with mild Coronavirus-19(COVID-19) disease. A total of 100 patients will be randomized to receive MTX-LDE or placebo each 7 days, up to 3 times, during in hospital treatment.
Description: Compare the duration of hospital stay between groups
Measure: Duration of hospital stay Time: 30 days after randomizationDescription: The secondary outcome is the need for mechanical ventilation between groups
Measure: Number of participants requiring mechanical ventilation Time: 15 days after randomizationDescription: The secondary outcome is the need for vasoactive drugs between groups
Measure: Number of participants requiring vasoactive drugs Time: 15 days after randomizationDescription: The secondary outcome is the need for renal replacement therapy between groups
Measure: Number of participants requiring renal replacement therapy Time: 15 days after randomizationDescription: The secondary outcome is the incidence of secondary infection between groups
Measure: Incidence of secondary infection Time: 15 days after randomizationDescription: The secondary outcome is the comparison of Sequential Organ Failure Assessment (SOFA) score between groups
Measure: Sequential Organ Failure Assessment (SOFA) score Time: Baseline and change from baseline to 15 days after randomizationDescription: The secondary outcome is the comparison of World Health Organization (WHO) COVID-19 clinical score between groups
Measure: World Health Organization (WHO) COVID-19 score Time: Baseline and change from baseline to 15 days after randomizationDescription: The secondary outcome is the comparison of IL-6 levels between groups
Measure: Interleukin 6 (IL-6) Time: Baseline and change from baseline to 15 days after randomizationDescription: The secondary outcome is the comparison of dimer-D levels between groups
Measure: Dimer-D Time: Baseline and change from baseline to 15 days after randomizationDescription: The secondary outcome is the comparison of chest CT scan between groups
Measure: Chest CT scan Time: Baseline and change from baseline to 15 days after randomizationDescription: The secondary outcome is the comparison of red blood cells; white blood cells;Platelets; Urea;Creatinine levels between groups
Measure: Incidence and severity of laboratory alterations Time: 30 days after randomizationDescription: Compare the incidence of clinical significant symptoms (new and persistent stomatitis, vomiting, diarrhea, alopecia, neurotoxicity, bradycardia, hypotension, local pain) reported between groups.
Measure: Clinical side effects Time: 30 days after randomizationDescription: Compare the incidence of other adverse events (not expected) between groups
Measure: Other adverse events Time: 30 days after randomizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports